Moderna and Merck have reported encouraging interim results from a large clinical trial testing a personalized cancer vaccine that utilizes mRNA technology, renewing interest in its potential to treat certain cancers. The experimental vaccine, known as intismeran autogene, in combination with Merck’s immunotherapy drug Keytruda, showed a reduction in the risk of recurrence and metastasis in melanoma patients following surgical removal of their tumors.

The vaccine is custom-made for each patient by sequencing their surgically excised tumor to identify up to 34 unique mutations. These mutations then serve as targets for the mRNA vaccine, which is administered alongside Keytruda infusions. The combination therapy aims to activate the patient’s immune system to recognize and attack residual cancer cells more effectively. Patients in the trial could receive up to nine doses of both the vaccine and Keytruda, spaced six weeks apart.

Experts have expressed optimism that this approach may be particularly effective in cancers characterized by high mutation rates, such as melanoma, lung, and colon cancers, where numerous tumor-specific mutations offer multiple targets for immune attack. Dr. Michael Atkins, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, noted that while such highly mutated tumors could be promising candidates for this therapy, it remains uncertain how well the vaccine platform will perform in other cancer types.

Building on the melanoma data, Merck and Moderna are conducting additional large trials in patients with non-small cell lung cancer following surgery. The companies are also evaluating the intismeran and Keytruda combination in mid-stage studies involving bladder and kidney cancers, along with early-stage trials in pancreatic and stomach cancers. Several data readouts from these ongoing studies are anticipated within the next one to two years.

While the interim findings offer a hopeful glimpse into personalized mRNA cancer vaccines, the available evidence remains limited and longer-term results are necessary to fully understand the safety and efficacy of this novel treatment approach across various cancer types.